Prior Authorization Form

Note: Please provide as much information as possible on this form. Missing data may cause processing delays for requested authorization(s). Attach additional sheets to this form if necessary.

Please fax the completed PA form and any additional informational sheets to Nirvanahealth at the following fax number: +1(866) 871-8565

Patient Information		Prescriber Information	
Patient Name:		Prescriber Name:	
Health Plan Name:		Prescriber Address:	
Patient Insurance Id:			
Patient Date of Birth:		Prescriber Phone:	( )
Patient Phone:		Prescriber Fax:	( )
		Prescriber Specialty:	
		Prescriber DEA:	
		Prescriber NPI:	

Medication & Medical Information	
Requested Drug(s) & Strength(s):	[ ] Afinitor Disperz 2 mg tablet for oral suspension [ ] Afinitor Disperz 3 mg tablet for oral suspension [ ] Afinitor Disperz 5 mg tablet for oral suspension
Requested Daily Quantity Limit – Amount:	
Requested Daily Quantity Limit – Days:	
Requested Quantity Limit Over Time – Amount:	
Requested Quantity Limit Over Time – Days:	
Requested Quantity Per Rx – Amount:	
Expected Length of Therapy:	
Directions:	
Diagnosis and Diagnosis Codes (ICD-10 Standard Codes):	
List drugs used previously to treat the same condition:	
Additional clinical information or history. Please include any relevant test results and/or medical record notes:	

Questionnaire

Q1: I, as the provider or designated representative of the provider, certify and attest that the information provided is complete and accurate and that, upon request, I shall provide any information to RxAdvance that RxAdvance determines is reasonably necessary to verify my responses. (Check only one that apply)

[ ] Yes

[ ] No

Q2: Is the member currently treated with this medication? (Check only one that apply)

[ ] Yes (please list start date of therapy (month/day/year))

[ ] No

Q3: What is the member's diagnosis? (Check only one that apply)

[ ] Subependymal Giant Cell Astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC)

[ ] TSC-associated partial-onset seizures

[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request)
_____(*Required)

Q4: What is the member's diagnosis? (Check only one that apply)

[ ] Subependymal Giant Cell Astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC)

[ ] TSC-associated partial-onset seizures

[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request)
_____(*Required)

Q5: Is the member a candidate for curative surgical resection concerning SEGA associated with TSC? (Check only one that apply)

[ ] Yes (please provide clinical rationale for the request) _____
(*Required)

[ ] No

Q6: Is the member 1 year of age or older? (Check only one that apply)

[ ] Yes

[ ] No (please specify member's age and provide clinical rationale for the request)
_____(*Required)

Q7: Does the medication prescribed by or in consultation with an oncologist? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____
(*Required)

Q8: Does the medication be used as adjunctive therapy for TSC-associated partial-onset seizures? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____
(*Required)

Q9: Is the member 2 years of age or older? (Check only one that apply)

[ ] Yes

[ ] No (please specify member's age and provide clinical rationale for the request)
_____(*Required)

Q10: Does the medication prescribed by or in consultation with a neurologist? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____
(*Required)

Prior Authorization Form

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, Insurer, Medical Group or its designated representatives may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.	
Signature of Prescriber or Authorized Representative:	Date:
Print Authorized Representative Name:	